Evercore ISI analyst Cory Kasimov reiterated an Outperform rating and $50.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'June 24, 2024 11:49 AM Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analystJune 24, 2024 7:58 AM BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive DataJune 24, 2024 7:10 AM